Further studies are needed to establish the risk of developing secondary comorbidities following lifestyle interventions for PCOS, to confirm whether the savings in all scenarios using the Elecsys AMH Plus immunoassay for PCOS diagnosis in our study are accurate. This evidence concerns the gene AMH and polycystic ovary syndrome.